期刊
ENDOCRINOLOGY
卷 152, 期 6, 页码 2492-2502出版社
ENDOCRINE SOC
DOI: 10.1210/en.2010-0941
关键词
-
资金
- CONRAD Foundation [CIG-05-105, CIG-05-107]
- National Institutes of Health [U01-HD060479]
- National Institute of Child Health and Human Development (SSCPRR) [U54-HD28934]
Here we investigated a pharmacological approach to inhibit spermatogenesis in the mouse model by manipulating retinoid signaling using low doses of the pan-retinoic acid receptor (RAR) antagonist BMS-189453. Spermatogenesis was disrupted, with a failure of spermatid alignment and sperm release and loss of germ cells into lumen, abnormalities that resembled those in vitamin A-deficient and RAR alpha-knockout testes. Importantly, the induced sterility was reversible. Enhanced efficacy and a lengthened infertility period with full recovery of spermatogenesis were observed using systematically modified dosing regimens. Hematology, serum chemistry, and hormonal and pathological evaluations revealed no detectable abnormalities or adverse side effects except the distinct testicular pathology. Our results suggest that testes are exquisitely sensitive to disruption of retinoid signaling and that RAR antagonists may represent new lead molecules in developing nonsteroidal male contraceptives. (Endocrinology 152: 2492-2502, 2011)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据